Related Experiment Video
Updated: Jan 9, 2026

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
Published on: June 2, 2019
Intravesicular gelation of mesenchymal stromal cell-derived microvesicles for enhanced therapeutic angiogenesis in
Chuang Liu1,2,3, Wenqi Xie1,2,3, Xian Li1,2,3
1School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P. R. China. msxlfu@scut.edu.cn.
Abstract:
Mesenchymal stromal cell-derived artificial microvesicles (MSC-MVs) hold significant promise as a cell-free alternative to traditional stem cell therapy for the treatment of lower limb ischemia. However, their fragile plasma membrane is highly susceptible to oxidative damage, environmental fluctuations, and long-term storage, often leading to membrane rupture, vesicle disintegration, and leakage of bioactive cargoes. Additionally, MSC-MVs can be contaminated by nuclear genes, limiting their safety and therapeutic applicability. In this study, we developed gelated microvesicles (gel-MVs) derived from enucleated MSCs by incorporating a polyethylene glycol diacrylate (PEGDA) polymer network within the vesicular lumen. This intravesicular gelation process stabilized the structure of MSC-MVs, effectively preventing vesicle degradation and content leakage. In vitro experiments demonstrated that gelation preserved the integrity of bioactive components and maintained their functional activity. In a murine lower limb ischemia model, gel-MVs significantly enhanced angiogenesis, restored blood perfusion, reduced apoptosis, and promoted tissue regeneration in ischemic limbs. This study introduces a novel strategy that integrates artificial polymer networks with natural microvesicles, providing a promising platform for engineering robust and functional MSC-MVs with enhanced therapeutic potential for clinical translation.

